CEPI has been on the front lines of vaccine development, working on manufacturing issues in parallel to clinical development. The organization has invested over $829 million on nine COVID-19 vaccine candidates with the ultimate goal of developing a successful vaccine in a 12- to 18-month timeframe. This agreement is part of an effort to scale up industrialization to proactively meet global vaccine needs.

Stevanato Group will provide pharma glass vials for 2 billion doses of COVID-19 vaccines under development and a "fast track" access to its glass vial forming lines to CEPI. Image courtesy of Stevanato Group.

Under the agreement, Stevanto Group will supply 100 million type 1 borosilicate glass vials. The vials will be able to hold up to 20 doses per vial. The Stevanto Group will also grant "fast track" access to its glass vial forming lines through its company Spami.

ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture...

Europe raises 7.4B euros for coronavirus response
On May 4, a group of nations and the European Commission raised 7.4 billion euros ($8 billion U.S.) to help make up for funding shortfalls in...

CEPI, Clover to partner on COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI) and Clover Biopharmaceuticals Australia plan to partner on the development of a COVID-19 vaccine.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Funding floodgates open for COVID-19 research
The impacts of the COVID-19 pandemic are being felt around the world. Researchers are working at a record-setting pace to understand the novel coronavirus...